Bioequivalence study of improved modified formulation of cilostazol 100 mg orally disintegrating tablet and currently marketed cilostazol 100 mg orally disintegrating tablet (Pletaal® OD tablet 100 mg) in healthy adult male subjects

Setsuo Hasegawa, Junko Inomata, Kiho Yano, Naoko Shimofurutani, Shuhei Ueda, Eiichi Saito

Research output: Contribution to journalArticle

Abstract

The cilostazol orally disintegrating tablet currently on the market (current ODT) was developed as a tablet for easier use in patients with difficulty of swallowing water. Cilostazol improved modified formulation orally disintegrating tablet (improved ODT) is a newly-developed formulation that dissolves in the oral cavity more quickly than the current ODT. The bioequivalence of one cilostazol 100 mg improved ODT and one cilostazol 100 mg current ODT, each taken with or without water, was evaluated in healthy adult male subjects in an open-label, randomized, 2-formulation, 2-treatment, 2-period crossover study. A total of 44 subjects were enrolled and 38 subjects completed the study. When administered without water, the differences in the mean log-transformed AUC60h, and Cmax values between the improved ODT and the current ODT (improved ODT-current ODT, point estimates) were respectively log (0.91) and log (1.03), with respective 90% confidence intervals of log (0.84) to log (0.98) and log (0.93) to log (1.15). When administered with water, the differences in the mean log-transformed AUC 60h and Cmax values between the improved ODT and the current ODT were both log (0.95), with respective 90% confidence intervals of log (0.89) to log (1.02) and log (0.83) to log (1.08). All values were within the range of the equivalence judgment criteria of log (0.8) to log (1.25) specified in the guideline for bioequivalence studies. Based on these results, one cilostazol 100 mg improved ODT was judged to be bioequivalent to one cilostazol 100 mg current ODT when administered either with or without water. All adverse events observed in either group were mild or moderate in severity, and other than one case of influenza, all adverse events were resolved without treatment. There were no deaths or other serious adverse events.

Original languageEnglish
Pages (from-to)955-964
Number of pages10
JournalJapanese Pharmacology and Therapeutics
Volume40
Issue number11
Publication statusPublished - 01-12-2012

Fingerprint

Therapeutic Equivalency
Tablets
Water
Confidence Intervals
cilostazol
Deglutition
Cross-Over Studies
Human Influenza
Area Under Curve
Mouth
Guidelines
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{fcb0c48604064ca2b0fe40d2b4b5d73e,
title = "Bioequivalence study of improved modified formulation of cilostazol 100 mg orally disintegrating tablet and currently marketed cilostazol 100 mg orally disintegrating tablet (Pletaal{\circledR} OD tablet 100 mg) in healthy adult male subjects",
abstract = "The cilostazol orally disintegrating tablet currently on the market (current ODT) was developed as a tablet for easier use in patients with difficulty of swallowing water. Cilostazol improved modified formulation orally disintegrating tablet (improved ODT) is a newly-developed formulation that dissolves in the oral cavity more quickly than the current ODT. The bioequivalence of one cilostazol 100 mg improved ODT and one cilostazol 100 mg current ODT, each taken with or without water, was evaluated in healthy adult male subjects in an open-label, randomized, 2-formulation, 2-treatment, 2-period crossover study. A total of 44 subjects were enrolled and 38 subjects completed the study. When administered without water, the differences in the mean log-transformed AUC60h, and Cmax values between the improved ODT and the current ODT (improved ODT-current ODT, point estimates) were respectively log (0.91) and log (1.03), with respective 90{\%} confidence intervals of log (0.84) to log (0.98) and log (0.93) to log (1.15). When administered with water, the differences in the mean log-transformed AUC 60h and Cmax values between the improved ODT and the current ODT were both log (0.95), with respective 90{\%} confidence intervals of log (0.89) to log (1.02) and log (0.83) to log (1.08). All values were within the range of the equivalence judgment criteria of log (0.8) to log (1.25) specified in the guideline for bioequivalence studies. Based on these results, one cilostazol 100 mg improved ODT was judged to be bioequivalent to one cilostazol 100 mg current ODT when administered either with or without water. All adverse events observed in either group were mild or moderate in severity, and other than one case of influenza, all adverse events were resolved without treatment. There were no deaths or other serious adverse events.",
author = "Setsuo Hasegawa and Junko Inomata and Kiho Yano and Naoko Shimofurutani and Shuhei Ueda and Eiichi Saito",
year = "2012",
month = "12",
day = "1",
language = "English",
volume = "40",
pages = "955--964",
journal = "Japanese Pharmacology and Therapeutics",
issn = "0386-3603",
publisher = "Life Science Publishing Co. Ltd",
number = "11",

}

TY - JOUR

T1 - Bioequivalence study of improved modified formulation of cilostazol 100 mg orally disintegrating tablet and currently marketed cilostazol 100 mg orally disintegrating tablet (Pletaal® OD tablet 100 mg) in healthy adult male subjects

AU - Hasegawa, Setsuo

AU - Inomata, Junko

AU - Yano, Kiho

AU - Shimofurutani, Naoko

AU - Ueda, Shuhei

AU - Saito, Eiichi

PY - 2012/12/1

Y1 - 2012/12/1

N2 - The cilostazol orally disintegrating tablet currently on the market (current ODT) was developed as a tablet for easier use in patients with difficulty of swallowing water. Cilostazol improved modified formulation orally disintegrating tablet (improved ODT) is a newly-developed formulation that dissolves in the oral cavity more quickly than the current ODT. The bioequivalence of one cilostazol 100 mg improved ODT and one cilostazol 100 mg current ODT, each taken with or without water, was evaluated in healthy adult male subjects in an open-label, randomized, 2-formulation, 2-treatment, 2-period crossover study. A total of 44 subjects were enrolled and 38 subjects completed the study. When administered without water, the differences in the mean log-transformed AUC60h, and Cmax values between the improved ODT and the current ODT (improved ODT-current ODT, point estimates) were respectively log (0.91) and log (1.03), with respective 90% confidence intervals of log (0.84) to log (0.98) and log (0.93) to log (1.15). When administered with water, the differences in the mean log-transformed AUC 60h and Cmax values between the improved ODT and the current ODT were both log (0.95), with respective 90% confidence intervals of log (0.89) to log (1.02) and log (0.83) to log (1.08). All values were within the range of the equivalence judgment criteria of log (0.8) to log (1.25) specified in the guideline for bioequivalence studies. Based on these results, one cilostazol 100 mg improved ODT was judged to be bioequivalent to one cilostazol 100 mg current ODT when administered either with or without water. All adverse events observed in either group were mild or moderate in severity, and other than one case of influenza, all adverse events were resolved without treatment. There were no deaths or other serious adverse events.

AB - The cilostazol orally disintegrating tablet currently on the market (current ODT) was developed as a tablet for easier use in patients with difficulty of swallowing water. Cilostazol improved modified formulation orally disintegrating tablet (improved ODT) is a newly-developed formulation that dissolves in the oral cavity more quickly than the current ODT. The bioequivalence of one cilostazol 100 mg improved ODT and one cilostazol 100 mg current ODT, each taken with or without water, was evaluated in healthy adult male subjects in an open-label, randomized, 2-formulation, 2-treatment, 2-period crossover study. A total of 44 subjects were enrolled and 38 subjects completed the study. When administered without water, the differences in the mean log-transformed AUC60h, and Cmax values between the improved ODT and the current ODT (improved ODT-current ODT, point estimates) were respectively log (0.91) and log (1.03), with respective 90% confidence intervals of log (0.84) to log (0.98) and log (0.93) to log (1.15). When administered with water, the differences in the mean log-transformed AUC 60h and Cmax values between the improved ODT and the current ODT were both log (0.95), with respective 90% confidence intervals of log (0.89) to log (1.02) and log (0.83) to log (1.08). All values were within the range of the equivalence judgment criteria of log (0.8) to log (1.25) specified in the guideline for bioequivalence studies. Based on these results, one cilostazol 100 mg improved ODT was judged to be bioequivalent to one cilostazol 100 mg current ODT when administered either with or without water. All adverse events observed in either group were mild or moderate in severity, and other than one case of influenza, all adverse events were resolved without treatment. There were no deaths or other serious adverse events.

UR - http://www.scopus.com/inward/record.url?scp=84871834772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871834772&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84871834772

VL - 40

SP - 955

EP - 964

JO - Japanese Pharmacology and Therapeutics

JF - Japanese Pharmacology and Therapeutics

SN - 0386-3603

IS - 11

ER -